{"title":"Cryptococcal meningitis complicating immunomodulatory drug maintenance therapy in patients with multiple myeloma: a report of two cases.","authors":"Fenfen He, Yadong Chen, Zhenchao Huang, Yongjiang Zheng","doi":"10.1007/s00277-026-06819-2","DOIUrl":"https://doi.org/10.1007/s00277-026-06819-2","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 3","pages":"98"},"PeriodicalIF":2.4,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146140734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-09DOI: 10.1007/s00277-026-06843-2
Robert Yuan, Yiyu Xie, Patricia M Miron, Anne W Higgins, Lloyd Hutchinson, Jan Cerny, Shyam A Patel
Somatic mutations within NRAS or KRAS are recurrent in acute myeloid leukemia (AML) and often arise as obligatory late events regarding AML ontogeny. RAS mutations have implications in solid cancers and in AML; however, their prognostic significance and codon-level characteristics are poorly understood, especially regarding response to intensive chemotherapy. There is an unmet need for targeting the RAS pathway. Herein, we performed clinico-genomic profiling of 89 patients with RAS-mutant AML, alongside 99 patients with RAS-wild-type AML. Median overall survival (OS) for RAS-mutant AML was shorter compared to RAS-wild-type AML (19.2 vs. 63.3 months, p = 0.05). For patients receiving cytarabine-based front-line chemotherapy, those with RAS mutations had shorter median OS compared to RAS-wild-type AML (27.1 vs. 122.2 months, p < 0.001). Within the RAS-mutant AML group, cytarabine-based front-line therapy resulted in longer median OS compared to front-line hypomethylating agents (27.1 vs. 13.2 months, p = 0.04). Hematopoietic cell transplantation (HCT) for RAS-mutant AML conferred longer median OS compared to no HCT (45.1 vs. 13.2 months, p = 0.004). There was no difference in survival among heterogeneous RAS-mutant subgroups (NRAS vs. KRAS vs. double-mutant) or among hotspot codons. Analysis of variant allele frequencies suggested that NRAS/KRAS mutations were subclonal. Although 80 (66.1%) of 121 total RAS mutations were found in codons G12 or G13, most substitutions were G12D or G13D, which are not targetable by commercial RASG12C inhibitors. This study sheds light on prognostic implications of RAS mutations and may inform extension of the therapeutic reach of RAS inhibitors to AML.
{"title":"Clinico-genomic characterization of RAS-mutant acute myeloid leukemia.","authors":"Robert Yuan, Yiyu Xie, Patricia M Miron, Anne W Higgins, Lloyd Hutchinson, Jan Cerny, Shyam A Patel","doi":"10.1007/s00277-026-06843-2","DOIUrl":"https://doi.org/10.1007/s00277-026-06843-2","url":null,"abstract":"<p><p>Somatic mutations within NRAS or KRAS are recurrent in acute myeloid leukemia (AML) and often arise as obligatory late events regarding AML ontogeny. RAS mutations have implications in solid cancers and in AML; however, their prognostic significance and codon-level characteristics are poorly understood, especially regarding response to intensive chemotherapy. There is an unmet need for targeting the RAS pathway. Herein, we performed clinico-genomic profiling of 89 patients with RAS-mutant AML, alongside 99 patients with RAS-wild-type AML. Median overall survival (OS) for RAS-mutant AML was shorter compared to RAS-wild-type AML (19.2 vs. 63.3 months, p = 0.05). For patients receiving cytarabine-based front-line chemotherapy, those with RAS mutations had shorter median OS compared to RAS-wild-type AML (27.1 vs. 122.2 months, p < 0.001). Within the RAS-mutant AML group, cytarabine-based front-line therapy resulted in longer median OS compared to front-line hypomethylating agents (27.1 vs. 13.2 months, p = 0.04). Hematopoietic cell transplantation (HCT) for RAS-mutant AML conferred longer median OS compared to no HCT (45.1 vs. 13.2 months, p = 0.004). There was no difference in survival among heterogeneous RAS-mutant subgroups (NRAS vs. KRAS vs. double-mutant) or among hotspot codons. Analysis of variant allele frequencies suggested that NRAS/KRAS mutations were subclonal. Although 80 (66.1%) of 121 total RAS mutations were found in codons G12 or G13, most substitutions were G12D or G13D, which are not targetable by commercial RAS<sup>G12C</sup> inhibitors. This study sheds light on prognostic implications of RAS mutations and may inform extension of the therapeutic reach of RAS inhibitors to AML.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 3","pages":"99"},"PeriodicalIF":2.4,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146140587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-09DOI: 10.1007/s00277-026-06857-w
Qing Qing Ye, Xian Gui Zhou, Guang Yang, Wan Tao Xie, An Yong Yu, Hai Zhen Duan
β-thalassemia is a hereditary hemolytic disorder. Non-transfusion-dependent patients typically present with mild anemic symptoms under normal conditions, but may develop severe anemia during stress states. Moreover, treatment is often challenging due to concurrent hypersplenism.This article reports a case of a young male patient with non-transfusion-dependent β-thalassemia who was admitted to the hospital due to a closed fracture of the right femur. After admission, the patient developed severe anemia and showed a poor response to blood transfusion therapy. Considering the association with hypersplenism, partial splenic embolization (PSE) was performed. Postoperatively, the patient's anemia improved significantly, and he successfully underwent closed reduction and intramedullary nailing for the right femoral fracture. The fracture site of the right femur healed well after surgery, and he was able to walk with the assistance of a single crutch. This case demonstrates that partial splenic embolization is an effective adjuvant treatment strategy for transfusion-refractory β-thalassemia individual with hypersplenism, providing a new approach for managing such complex clinical scenarios.
{"title":"Overcoming transfusion-refractory anemia: partial splenic embolization to facilitate orthopedic surgery in β-thalassemia.","authors":"Qing Qing Ye, Xian Gui Zhou, Guang Yang, Wan Tao Xie, An Yong Yu, Hai Zhen Duan","doi":"10.1007/s00277-026-06857-w","DOIUrl":"https://doi.org/10.1007/s00277-026-06857-w","url":null,"abstract":"<p><p>β-thalassemia is a hereditary hemolytic disorder. Non-transfusion-dependent patients typically present with mild anemic symptoms under normal conditions, but may develop severe anemia during stress states. Moreover, treatment is often challenging due to concurrent hypersplenism.This article reports a case of a young male patient with non-transfusion-dependent β-thalassemia who was admitted to the hospital due to a closed fracture of the right femur. After admission, the patient developed severe anemia and showed a poor response to blood transfusion therapy. Considering the association with hypersplenism, partial splenic embolization (PSE) was performed. Postoperatively, the patient's anemia improved significantly, and he successfully underwent closed reduction and intramedullary nailing for the right femoral fracture. The fracture site of the right femur healed well after surgery, and he was able to walk with the assistance of a single crutch. This case demonstrates that partial splenic embolization is an effective adjuvant treatment strategy for transfusion-refractory β-thalassemia individual with hypersplenism, providing a new approach for managing such complex clinical scenarios.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 3","pages":"101"},"PeriodicalIF":2.4,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146140728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-09DOI: 10.1007/s00277-026-06768-w
Natalie Neumark, Katarzyna Aleksandra Jalowiec, Andre Tichelli, Naomi Porret, Linet Njue, Kristina Vrotniakaite-Bajerciene, Raja Prince-Eladnani, Anne Angelillo-Scherrer, Sara C Meyer, Alicia Rovó
{"title":"Long-term real-world thrombotic and clinical outcomes in polycythemia vera - a hospital-based i2b2 cohort study.","authors":"Natalie Neumark, Katarzyna Aleksandra Jalowiec, Andre Tichelli, Naomi Porret, Linet Njue, Kristina Vrotniakaite-Bajerciene, Raja Prince-Eladnani, Anne Angelillo-Scherrer, Sara C Meyer, Alicia Rovó","doi":"10.1007/s00277-026-06768-w","DOIUrl":"https://doi.org/10.1007/s00277-026-06768-w","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 3","pages":"100"},"PeriodicalIF":2.4,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146140753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-07DOI: 10.1007/s00277-026-06884-7
Biju George, Reuben Cecil Ross, Sharat Damodar, Tulika Seth, Kanti Tuphan Dolai, Saswata Banerjee, Rajan Manguesh, Pankaj Malhotra
{"title":"Correction to: A meta-analysis of immunosuppressive and Pharmacological therapies in aplastic anaemia with and without Indigenous equine antithymocyte Globulin (eATG).","authors":"Biju George, Reuben Cecil Ross, Sharat Damodar, Tulika Seth, Kanti Tuphan Dolai, Saswata Banerjee, Rajan Manguesh, Pankaj Malhotra","doi":"10.1007/s00277-026-06884-7","DOIUrl":"10.1007/s00277-026-06884-7","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 3","pages":"97"},"PeriodicalIF":2.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12881044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146130925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-07DOI: 10.1007/s00277-026-06866-9
Jesús Ardila, Melissa Diaz-Puentes, Margarita Guerrero, Andrés Escobar, Jhon Avila-Rueda, Mauricio Jaramillo, Diana Buitrago, Jose Restrepo, Claudia Hernández-Castillo, Laura Prieto-Pinto
{"title":"Factors contributing to the development of hemophilic arthropathy: A real-world study.","authors":"Jesús Ardila, Melissa Diaz-Puentes, Margarita Guerrero, Andrés Escobar, Jhon Avila-Rueda, Mauricio Jaramillo, Diana Buitrago, Jose Restrepo, Claudia Hernández-Castillo, Laura Prieto-Pinto","doi":"10.1007/s00277-026-06866-9","DOIUrl":"10.1007/s00277-026-06866-9","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 3","pages":"96"},"PeriodicalIF":2.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12881001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146130934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1007/s00277-026-06851-2
Jun Ho Yi, Dok Hyun Yoon, Sung-Soo Park, Chang-Ki Min, Ji Hyun Lee, Sung-Hoon Jung, Youngil Koh, Hyun Jung Lee, Jae-Cheol Jo, Kihyun Kim
{"title":"Real-world outcomes of SLiM-only multiple myeloma: Korean Multicenter Retrospective analysis (KMM2401 study).","authors":"Jun Ho Yi, Dok Hyun Yoon, Sung-Soo Park, Chang-Ki Min, Ji Hyun Lee, Sung-Hoon Jung, Youngil Koh, Hyun Jung Lee, Jae-Cheol Jo, Kihyun Kim","doi":"10.1007/s00277-026-06851-2","DOIUrl":"10.1007/s00277-026-06851-2","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 3","pages":"93"},"PeriodicalIF":2.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12881067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146130907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Platelet-neutrophil ratio as a potential biomarker for stroke risk stratification in children and young adults with sickle cell anaemia in resource poor settings.","authors":"Chisom Adaobi Nri-Ezedi, Chilota Chibuife Efobi, Deepika Darbari, Nana-Bilkisu Habib, Andrew Campbell","doi":"10.1007/s00277-026-06859-8","DOIUrl":"10.1007/s00277-026-06859-8","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 3","pages":"92"},"PeriodicalIF":2.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12881123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146130981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1007/s00277-026-06863-y
Theerin Lanamtieng, Anna Mervaala-Muroke, Laura Toivanen, Kimmo Porkka, Oscar Brück
{"title":"Novel therapies in myeloid neoplasms show limited benefit and increased costs over 15 years of follow-up in Southern Finland.","authors":"Theerin Lanamtieng, Anna Mervaala-Muroke, Laura Toivanen, Kimmo Porkka, Oscar Brück","doi":"10.1007/s00277-026-06863-y","DOIUrl":"10.1007/s00277-026-06863-y","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 3","pages":"94"},"PeriodicalIF":2.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12881082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146130984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1007/s00277-026-06876-7
Sophia Delicou, Aikaterini Xydaki, Vassiliki Kamposou, Sabrina Goga, Anthimos Papadopoulos, Christina Rina, Maria Moraki
{"title":"Epidemiological and comorbidity burden in transfusion-dependent patients with thalassemia and sickle cell disease in Greece.","authors":"Sophia Delicou, Aikaterini Xydaki, Vassiliki Kamposou, Sabrina Goga, Anthimos Papadopoulos, Christina Rina, Maria Moraki","doi":"10.1007/s00277-026-06876-7","DOIUrl":"10.1007/s00277-026-06876-7","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 3","pages":"95"},"PeriodicalIF":2.4,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12881026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146130989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号